[CMV pp65 gene modified dendritic cells activate autologous T cells]

Area of Science:

• Immunology
• Virology
• Cell Biology

Context:

• Cytomegalovirus (CMV) infection is a significant threat for patients with chronic graft versus host disease (cGVHD).
• Effective immune surveillance against CMV relies heavily on T cell responses.
• Developing strategies to bolster CMV-specific immunity is crucial for managing cGVHD complications.

Purpose:

• To investigate the potential of modifying dendritic cells (DCs) with the Cytomegalovirus (CMV) pp65 gene to activate autologous T cells.
• To assess the efficacy of lentivirus-mediated gene delivery for introducing the CMV pp65 gene into mouse DCs.
• To evaluate the capacity of mature, pp65-modified DCs to induce CMV-specific T cell activation and cytokine production.

Summary:

• Lentivirus system successfully introduced the CMV pp65 gene into mouse DCs with optimal efficiency.
• Mature DCs expressing the CMV pp65 gene, induced by CpG-DNA, specifically stimulated autologous naive T cells to express CD69.
• These modified DCs also promoted the production of IFN-gamma by autologous CD4+ and CD8+ T cells, indicating successful activation of CMV-specific T lymphocytes in vitro.

Impact:

• Demonstrates a potential therapeutic approach for enhancing CMV-specific T cell immunity in the context of cGVHD.
• Provides a foundation for further research into cell-based immunotherapies for viral complications post-transplantation.
• Highlights the role of engineered dendritic cells in stimulating adaptive immune responses against specific pathogens.